Table 1A

Baseline characteristics

Studies	N (total)	n (ULT)	Population, country	Age, yrs, mean (SD)	Male,(%)	Disease duration, yrs, mean (SD)	Medications	Quality
Prescription claims
Sarawate et al, 200617	5942	2405	Managed care database, USA	57.4 (14.1)*	76.4*	NS	Allopurinol	4
Briesacher et al, 200818		9715	MEDSTAT database, USA	58.7 (0.14)	77.5	NS	Allopurinol, uricosurics	4
Harrold et al, 200924		4166	Integrated delivery Systems, USA	62 (14)	75	NS	Allopurinol, probenecid, sulfinpyrazone	4
Halpern et al, 200930	18 243	10 070	Claims database, USA	Mean 53.9	84.2	NS	Allopurinol	4
Rashid et al, 201229		9288	KPSC healthcare, USA	Mean 60	78	NS	Allopurinol	4
Horsburgh et al, 201419	27 243	732	Community pharmacy dispensing databases, New Zealand	NA	39.5†	NS	Allopurinol	4
Singh, 201423		43	Outpatient clinic, USA	63.9 (9.9)	67	NS	Allopurinol, febuxostat	2
McGowan et al, 201622	34 634	15 908	HSE-PCRS scheme database, Ireland	Mean 65.2*	73*	NS	Allopurinol, febuxostat, probenecid, sulfinpyrazone	3
Tan et al, 201632		91	Hospital clinics, Singapore	53.5 (16.9)	92.3	NS	Allopurinol, probenecid	2
Solomon et al, 200821		9823	Medicare and PACE enrollees, USA	Mean 79	28†	NS	Allopurinol	4
Park et al, 201226	352	242	Scott & White Health Plan, USA	61.02 (15.33)*	72.4*†	NS	Allopurinol, febuxostat, probenecid	4
Zandman-Goddard et al, 201320		7644	MHS database, Israel	NA	72	NS	Allopurinol	4
Mantarro et al, 201531		3727	HSD database, Italy	Mean 65	80	NS	Allopurinol	4
Rashid et al, 201527		8288	Clinical and administrative databases, USA	NA	79.80	NS	Allopurinol, febuxostat, probenecid	4
Kuo et al, 201528		49 395	GPRD database, UK	NA	NA	NS	ULT	4
Riedel et al, 200425	9482	5597	IPA plans, USA	51(11)*	82.1*	NS	Allopurinol	4
Pill counts
Lee et al, 201633		132	Outpatient clinic, Korea	51.9 (10.4)	100	100.0 (89.1)‡	Allopurinol, febuxostat	2
Self-report
Silva et al, 201035		34	Outpatient, Spain	57.1 (11.8)	94.1†	NS	Allopurinol, benzbromarone	1
Singh et al, 201634	499	251	People visiting the Gout and Uric Acid Education Society’s website, USA	56.3 (12.6)*	73.7*	NS	Allopurinol, febuxostat	5
Interview
Martini et al, 201236	60	56	Community pharmacies, New Zealand	Mean 61*	90*	NS	Allopurinol	2
Sheng et al, 201438	161	80†	Gout Clinic, China	NA	NA	NS	ULD	1
van Onna et al, 201537	15	12	Outpatient clinic and primary care practices, The Netherlands	63 (12)*	93.3*†	11(7)*	ULT	2

*Data for total population.
†Calculated based on data provided in the article.
‡Disease duration (months).
cross, cross-sectional; NA, not applicable; NS, not stated; ULD, urate-lowering drugs; ULT, urate-lowering therapy; yr, year.